May 13 |
Denali Therapeutics: MPS Treatment Program Continues With End Of 2024 Data
|
May 12 |
Cantor picks 14 undervalued biotech stocks worth a second look
|
May 11 |
The Consensus EPS Estimates For Denali Therapeutics Inc. (NASDAQ:DNLI) Just Fell Dramatically
|
May 9 |
Denali Therapeutics First Quarter 2024 Earnings: US$0.68 loss per share (vs US$0.80 loss in 1Q 2023)
|
May 8 |
Denali (DNLI) Q1 Earnings Miss, Pipeline Progress in Focus
|
May 7 |
Denali Therapeutics Q1 2024 Earnings: Misses Revenue Estimates Amid Strategic Shifts
|
May 7 |
Denali Therapeutics GAAP EPS of -$0.68 beats by $0.02
|
May 7 |
Denali Therapeutics Reports First Quarter 2024 Financial Results and Business Highlights
|
May 1 |
Denali Therapeutics Announces Completion of Enrollment for Regimen G Evaluating eIF2B Agonist DNL343 in the Phase 2/3 HEALEY ALS Platform Trial
|
Apr 29 |
Is There An Opportunity With Denali Therapeutics Inc.'s (NASDAQ:DNLI) 50% Undervaluation?
|